1upj

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 4: Line 4:
==Overview==
==Overview==
-
The low oral bioavailability and rapid biliary excretion of, peptide-derived HIV protease inhibitors have limited their utility as, potential therapeutic agents. Our broad screening program to discover, nonpeptidic HIV protease inhibitors had previously identified compound II, (phenprocoumon, K(i) = 1 muM) as a lead template. Crystal structures of, HIV protease complexes containing the peptide-derived inhibitor I, (1-(naphthoxyacetyl)-L-histidyl-5(S)-amino-6-cyclohexyl-3, (R),4(R)-dihydroxy-2(R)-isopropylhexanoyl-L-isoleucine, N-(2-pyridylmethyl)amide) and nonpeptidic inhibitors, such as, phenprocoumon (compound II), provided a rational basis for the, structure-based design of more active analogues. This investigation, reports on the important finding of a carboxamide functionally, appropriately added to the 4-hydroxycoumarin and the 4-hydroxy-2-pyrone, templates which resulted in a new promising series of nonpeptidic HIV, protease inhibitors with improved enzyme-binding affinity. The most active, diastereomer of the carboxamide-containing compound XXIV inhibited HIV-1, protease with a K(i) value of 0.0014 muM. This research provides a new, design direction for the discovery of more potent HIV protease inhibitors, as potential therapeutic agents for the treatment of HIV infection.
+
The low oral bioavailability and rapid biliary excretion of peptide-derived HIV protease inhibitors have limited their utility as potential therapeutic agents. Our broad screening program to discover nonpeptidic HIV protease inhibitors had previously identified compound II (phenprocoumon, K(i) = 1 muM) as a lead template. Crystal structures of HIV protease complexes containing the peptide-derived inhibitor I (1-(naphthoxyacetyl)-L-histidyl-5(S)-amino-6-cyclohexyl-3 (R),4(R)-dihydroxy-2(R)-isopropylhexanoyl-L-isoleucine N-(2-pyridylmethyl)amide) and nonpeptidic inhibitors, such as phenprocoumon (compound II), provided a rational basis for the structure-based design of more active analogues. This investigation reports on the important finding of a carboxamide functionally appropriately added to the 4-hydroxycoumarin and the 4-hydroxy-2-pyrone templates which resulted in a new promising series of nonpeptidic HIV protease inhibitors with improved enzyme-binding affinity. The most active diastereomer of the carboxamide-containing compound XXIV inhibited HIV-1 protease with a K(i) value of 0.0014 muM. This research provides a new design direction for the discovery of more potent HIV protease inhibitors as potential therapeutic agents for the treatment of HIV infection.
==About this Structure==
==About this Structure==
Line 13: Line 13:
[[Category: Human immunodeficiency virus 1]]
[[Category: Human immunodeficiency virus 1]]
[[Category: Single protein]]
[[Category: Single protein]]
-
[[Category: Janakiraman, M.N.]]
+
[[Category: Janakiraman, M N.]]
-
[[Category: Mulichak, A.M.]]
+
[[Category: Mulichak, A M.]]
-
[[Category: Watenpaugh, K.D.]]
+
[[Category: Watenpaugh, K D.]]
[[Category: U01]]
[[Category: U01]]
[[Category: hydrolase (acid protease)]]
[[Category: hydrolase (acid protease)]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Fri Feb 15 17:03:35 2008''
+
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 15:27:01 2008''

Revision as of 13:27, 21 February 2008


1upj, resolution 2.22Å

Drag the structure with the mouse to rotate

HIV-1 PROTEASE COMPLEX WITH U095438 [3-[1-(4-BROMOPHENYL) ISOBUTYL]-4-HYDROXYCOUMARIN

Overview

The low oral bioavailability and rapid biliary excretion of peptide-derived HIV protease inhibitors have limited their utility as potential therapeutic agents. Our broad screening program to discover nonpeptidic HIV protease inhibitors had previously identified compound II (phenprocoumon, K(i) = 1 muM) as a lead template. Crystal structures of HIV protease complexes containing the peptide-derived inhibitor I (1-(naphthoxyacetyl)-L-histidyl-5(S)-amino-6-cyclohexyl-3 (R),4(R)-dihydroxy-2(R)-isopropylhexanoyl-L-isoleucine N-(2-pyridylmethyl)amide) and nonpeptidic inhibitors, such as phenprocoumon (compound II), provided a rational basis for the structure-based design of more active analogues. This investigation reports on the important finding of a carboxamide functionally appropriately added to the 4-hydroxycoumarin and the 4-hydroxy-2-pyrone templates which resulted in a new promising series of nonpeptidic HIV protease inhibitors with improved enzyme-binding affinity. The most active diastereomer of the carboxamide-containing compound XXIV inhibited HIV-1 protease with a K(i) value of 0.0014 muM. This research provides a new design direction for the discovery of more potent HIV protease inhibitors as potential therapeutic agents for the treatment of HIV infection.

About this Structure

1UPJ is a Single protein structure of sequence from Human immunodeficiency virus 1 with as ligand. Full crystallographic information is available from OCA.

Reference

Structure-based design of novel HIV protease inhibitors: carboxamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent nonpeptidic inhibitors., Thaisrivongs S, Watenpaugh KD, Howe WJ, Tomich PK, Dolak LA, Chong KT, Tomich CC, Tomasselli AG, Turner SR, Strohbach JW, et al., J Med Chem. 1995 Sep 1;38(18):3624-37. PMID:7658450

Page seeded by OCA on Thu Feb 21 15:27:01 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools